BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 29507093)

  • 1. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
    Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
    J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
    Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
    Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.
    Yin H; Xue W; Chen S; Bogorad RL; Benedetti E; Grompe M; Koteliansky V; Sharp PA; Jacks T; Anderson DG
    Nat Biotechnol; 2014 Jun; 32(6):551-3. PubMed ID: 24681508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo.
    Yin H; Song CQ; Dorkin JR; Zhu LJ; Li Y; Wu Q; Park A; Yang J; Suresh S; Bizhanova A; Gupta A; Bolukbasi MF; Walsh S; Bogorad RL; Gao G; Weng Z; Dong Y; Koteliansky V; Wolfe SA; Langer R; Xue W; Anderson DG
    Nat Biotechnol; 2016 Mar; 34(3):328-33. PubMed ID: 26829318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenine base editing in an adult mouse model of tyrosinaemia.
    Song CQ; Jiang T; Richter M; Rhym LH; Koblan LW; Zafra MP; Schatoff EM; Doman JL; Cao Y; Dow LE; Zhu LJ; Anderson DG; Liu DR; Yin H; Xue W
    Nat Biomed Eng; 2020 Jan; 4(1):125-130. PubMed ID: 31740768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
    Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
    Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of an Inherited Metabolic Liver Disease through Creation of a De Novo Start Codon by Cytidine Base Editing.
    Yang L; Wang L; Huo Y; Chen X; Yin S; Hu Y; Zhang X; Zheng R; Geng H; Han H; Ma X; Liu M; Li H; Yu W; Liu M; Wang J; Li D
    Mol Ther; 2020 Jul; 28(7):1673-1683. PubMed ID: 32413280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I.
    Li N; Gou S; Wang J; Zhang Q; Huang X; Xie J; Li L; Jin Q; Ouyang Z; Chen F; Ge W; Shi H; Liang Y; Zhuang Z; Zhao X; Lian M; Ye Y; Quan L; Wu H; Lai L; Wang K
    Mol Ther; 2021 Mar; 29(3):1001-1015. PubMed ID: 33221434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of single guided Cas9 nickase to facilitate precise and efficient genome editing in human iPSCs.
    Li PP; Margolis RL
    Sci Rep; 2021 May; 11(1):9865. PubMed ID: 33972655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of an Efficient Genome Editing Tool in Bacillus licheniformis Using CRISPR-Cas9 Nickase.
    Li K; Cai D; Wang Z; He Z; Chen S
    Appl Environ Microbiol; 2018 Mar; 84(6):. PubMed ID: 29330178
    [No Abstract]   [Full Text] [Related]  

  • 13. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations.
    Cullot G; Boutin J; Toutain J; Prat F; Pennamen P; Rooryck C; Teichmann M; Rousseau E; Lamrissi-Garcia I; Guyonnet-Duperat V; Bibeyran A; Lalanne M; Prouzet-Mauléon V; Turcq B; Ged C; Blouin JM; Richard E; Dabernat S; Moreau-Gaudry F; Bedel A
    Nat Commun; 2019 Mar; 10(1):1136. PubMed ID: 30850590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
    Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
    Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1.
    Hickey RD; Nicolas CT; Allen K; Mao S; Elgilani F; Glorioso J; Amiot B; VanLith C; Guthman R; Du Z; Chen H; Harding CO; Kaiser RA; Nyberg SL; Lillegard JB
    Cell Transplant; 2019 Jan; 28(1):79-88. PubMed ID: 30477316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced Liver Regeneration Enhances CRISPR/Cas9-Mediated Gene Repair in Tyrosinemia Type 1.
    Zhang QS; Tiyaboonchai A; Nygaard S; Baradar K; Major A; Balaji N; Grompe M
    Hum Gene Ther; 2021 Mar; 32(5-6):294-301. PubMed ID: 32729326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent mutation reversion inversely correlates with clinical severity in a genetic liver disease, hereditary tyrosinemia.
    Demers SI; Russo P; Lettre F; Tanguay RM
    Hum Pathol; 2003 Dec; 34(12):1313-20. PubMed ID: 14691918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.
    Pankowicz FP; Barzi M; Legras X; Hubert L; Mi T; Tomolonis JA; Ravishankar M; Sun Q; Yang D; Borowiak M; Sumazin P; Elsea SH; Bissig-Choisat B; Bissig KD
    Nat Commun; 2016 Aug; 7():12642. PubMed ID: 27572891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.
    Li L; Zhang Q; Yang H; Zou Q; Lai C; Jiang F; Zhao P; Luo Z; Yang J; Chen Q; Wang Y; Newsome PN; Frampton J; Maxwell PH; Li W; Chen S; Wang D; Siu TS; Tam S; Tse HF; Qin B; Bao X; Esteban MA; Lai L
    J Biol Chem; 2017 Mar; 292(11):4755-4763. PubMed ID: 28053091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
    Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.